靶向纤溶酶原激活物抑制剂-1在 COVID-19 中的治疗潜力。
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19.
机构信息
Evotec (UK) Ltd, Abingdon, UK.
Evotec (UK) Ltd, Abingdon, UK.
出版信息
Trends Pharmacol Sci. 2021 Jun;42(6):431-433. doi: 10.1016/j.tips.2021.03.006. Epub 2021 Mar 26.
Abstract
Latest research shows that SERPINE1 overexpression has an important role in Coronavirus 2019 (COVID-19)-associated coagulopathy leading to acute respiratory distress syndrome (ARDS). However, ways to target this protein remain elusive. In this forum, we discuss recent evidence linking SERPINE1 with COVID-19-related ARDS and summarize the available data on inhibitors of this target.
摘要
最新研究表明，丝氨酸蛋白酶抑制剂 1（SERPINE1）过表达在 2019 年冠状病毒（COVID-19）相关凝血功能障碍导致的急性呼吸窘迫综合征（ARDS）中起重要作用。然而，针对这种蛋白的方法仍然难以捉摸。在这个论坛中，我们讨论了最近将 SERPINE1 与 COVID-19 相关 ARDS 联系起来的证据，并总结了该靶点抑制剂的现有数据。
Zotero 插件